Perspectives on metals-based radioimmunotherapy (RIT): moving forward

White, Jordan M.; Escorcia, Freddy E.; Viola, Nerissa T.

doi:10.7150/thno.57177

Cited by 38 publications

(24 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These have been most commonly antibodies, antibody fragments, peptides, small molecules and even nanoparticles. 193,215 Antibodies are heavy, Y-shaped proteins with a high molecular weight of roughly 150 kDa. 216 Monoclonal antibodies (mAbs) are designed to bind to only one target, meaning that they can be widely utilised in the therapy of various cancers, although, since their discovery, their use has not been met with the expected popularity.…”

Section: Choice Of Targeting Vectormentioning

confidence: 99%

“…34,89,189,[221][222][223] Antibody fragments have been explored as an alternative targeting vector to full monoclonal antibodies and are deemed to have more favourable pharmacokinetics. 215,224 They are theoretically able to retain the strong target-binding affinity of full mAbs, but their smaller size means they have faster blood-clearance via the kidneys with low liver accumulation. 215 Radiolabelling of antibody fragments has been explored with radiorhenium, 225 with the scope for this method of tumour targeting set to expand to in the same way as seen with 99m Tc.…”

Section: Choice Of Targeting Vectormentioning

confidence: 99%

See 1 more Smart Citation

Bifunctional chelators for radiorhenium: past, present and future outlook

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Choice Of Targeting Vectormentioning

confidence: 99%

Section: Choice Of Targeting Vectormentioning

confidence: 99%

Bifunctional chelators for radiorhenium: past, present and future outlook

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Furthermore, hypoxia, which is present in most of solid tumors, reduces radiation efficiency, except for that of alpha particles, which do not need oxygen. Solid tumor features that modulate RIT efficiency were clearly described in a recent review [ 93 ]. To circumvent these limitations, one solution could be to perform repeated treatment cycles to limit radiotoxicity.…”

Section: Last Ten Years Publications Involving Rit Protocolsmentioning

confidence: 99%

“…One problem of this very attractive strategy is the difficulty of acquiring radionuclides [ 94 ]. For instance, the production of Actinium-225 in 2018 would have only supported the treatment for several hundred patients [ 93 ].…”

Section: Last Ten Years Publications Involving Rit Protocolsmentioning

confidence: 99%

Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials

Rondon

Rouanet

Degoul

2021

Cancers

View full text Add to dashboard Cite

The specific irradiation of tumors with selective radiolabeled antibodies constitutes an attractive therapeutic approach. Consequent preclinical research has been conducted by both biologists to identify pertinent targets and to select corresponding antibodies (mAb) and by radiochemists to radiolabel mAbs. These numerous preclinical investigations have ascertained the therapeutic interest of radioimmunotherapy (RIT) protocols in mice models. Here, we summarize the clinical studies that have been performed the last decade, including clinical trials (phases I, II, and III), prospective and retrospective studies, and cases series. We thereby reported 92 clinical studies. Among them, 62 concern the treatment of hematological malignancies, and 30 concern solid tumors. For hematologic diseases, the analysis was complex due to the high discrepancy of therapeutic strategies (first-line therapy, consolidation, stem cell transplantation conditioning) as well as the high variety of malignancies that were treated. The clinical studies from the last decade failed to expand anti-CD20 RIT indications but confirmed that RIT using radiolabeled anti-CD20 remains a pertinent choice for patients with relapse follicular lymphomas. For solid tumors, the positive benefit of RIT is more mitigated, apart for few malignancies that can be treated locally. Clinical trials also demonstrated the potential of some antibody formats, such as F(ab′)2, which has already been approved by the China State FDA under the trend name Licartin®. Despite disparate results, mAb fragments are an interesting prospect for the improvement of RIT efficiency as well as for pretargeted strategies that delay the injection of radioactive treatments from the mAb ones.

show abstract

“…В случае медуллярного рака данная находка представляется многообещающей, с учетом того, что эта агрессивная нейроэндокринная карцинома крайне редко и слабо экспрессирует рецепторы к соматостатину, поэтому возникают проблемы с молекулярной визуализацией и радионуклидной терапией. Это особенно актуально в связи с тем, что 40-50% медуллярных карцином первично выявляются на стадии с отдаленными метастазами [9].…”

Section: интеграционная модель радиотераностикиunclassified

Radiotheranostics of neuroendocrine neoplasms: <i>quo vadis</i>

Rumyantsev¹

2021

Alʹm. klin. med.

View full text Add to dashboard Cite

Neuroendocrine neoplasms are grouped based on their neuroendocrine origin and represented by a heterogeneous tumor cluster with various malignancy potentials and types of biological behavior. These tumors can localize anywhere, but most commonly within the gastrointestinal tract. The ability of tumor cells to express specific receptors and particulars of their metabolism make it possible to successfully use molecular visualization (single-photon emission computed tomography / positron emission tomography) and radiotargeted therapy for diagnosis and treatment of patients with neuroendocrine tumors. In clinical practice, somatostatin receptor (receptors type 2) radiotheranostics has been used most widely. Improvement of diagnostic and therapeutic characteristics of new radioligands, discovery of new receptor and metabolic targets, widening of the medical isotope spectrum and development of new theranostic pairs open wide horizons for radiotheranostics as an integral field in modern biomedicine. The paper summarizes the worldwide experience, highlights the state-of-the-art and future development of radiotheranostics of neuroendocrine tumors.

show abstract

Perspectives on metals-based radioimmunotherapy (RIT): moving forward

Cited by 38 publications

References 169 publications

Bifunctional chelators for radiorhenium: past, present and future outlook

Bifunctional chelators for radiorhenium: past, present and future outlook

Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials

Radiotheranostics of neuroendocrine neoplasms: <i>quo vadis</i>

Contact Info

Product

Resources

About